FRANKLIN OPHTHALMIC INSTRUMENTS CO INC
10QSB, 1996-06-24
PROFESSIONAL & COMMERCIAL EQUIPMENT & SUPPLIES
Previous: KEMPER TAX EXEMPT INSURED INCOME TRUST SER A90 & MS SER 65, 24F-2NT, 1996-06-24
Next: ACCOLADE FUNDS, 497, 1996-06-24



<PAGE>
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                       ----------------------------------

                                   FORM 10-QSB
                          QUARTERLY REPORT PURSUANT TO
           SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
                  FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1996
                           Commission File No. 0-21852
                       ----------------------------------

                    FRANKLIN OPHTHALMIC INSTRUMENTS CO., INC.
        (Exact name of small business issuer as specified in its charter)



            Delaware                                   94-3174941
    (State or other jurisdiction                     (I.R.S. Employer
of incorporation or organization)                 Identification Number)



        1265 Naperville Drive, Romeoville, Illinois 60446 (708) 759-7666
   (Address and telephone number of registrant's principal executive offices)

                       ----------------------------------




Indicate  by check  mark  whether  the  Registrant:  (1) has filed  all  reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
Registrant  was required to file such  reports) and (2) has been subject to such
filing requirements for the past 90 days.



                        YES |X|            NO |_|



As of June 13, 1996 the Registrant had  outstanding  7,610,026  shares of common
stock.



<PAGE>






                    FRANKLIN OPHTHALMIC INSTRUMENTS CO., INC.
                                   FORM 10-QSB
                      FOR THE QUARTER ENDED MARCH 31, 1996

                                      INDEX

PART I.......................................................................1
     Item 1.  Financial Statements.......................................... 1
               Condensed Consolidated Balance Sheet......................... 1
               Condensed Consolidated Statement of Operations............... 3
               Condensed Consolidated Statements of Cash Flows.............. 4
               Notes to Condensed Consolidated Financial Statements......... 5
     Item 2.  Management's Discussion and Analysis of Financial Condition
              and Results of Operations.....................................10

PART II.....................................................................14
     Item 1.  Legal Proceedings.............................................14
     Item 2.  Changes in Securities.........................................14
     Item 3.  Defaults Upon Senior Securities...............................14
     Item 4.  Submission of Matters to a Vote of Security Holders...........14
     Item 5.  Other Information and Subsequent Events.......................14
     Item 6.  Exhibits and Reports on Form 8-K..............................14

Signatures..................................................................15



<PAGE>



                    FRANKLIN OPHTHALMIC INSTRUMENTS CO., INC.

                      CONDENSED CONSOLIDATED BALANCE SHEETS


                                     ASSETS

  <TABLE>
<CAPTION>
                                                                  March 31,           September 30,
                                                                    1996                  1995
                                                                (Unaudited)
                                                            -------------------   -------------------
Current Assets:
<S>                                                           <C>                    <C>           
   Cash and cash equivalents                                  $             -        $            -
   Accounts receivable, less allowance for doubtful
      accounts of $337,333 and $349,136, respectively                 677,182               995,665      
   Inventory, less valuation allowance of $150,000                  2,108,334             2,545,940      
   Prepaid expenses and other assets                                  102,883                28,296      
                                                                --------------       --------------     
                                                                                         
         Total current assets                                       2,888,399             3,569,901      
                                                                --------------       --------------     
                                                                                                    
                                                                         
   Property and equipment, at cost:                                                                  
      Furniture and equipment                                         601,034               599,307      
      Automobiles and trucks                                          119,193               119,193                         
      Leasehold improvements                                          109,408               109,408      
                                                                --------------       --------------  
                                                                      829,635               827,908                            
   Less: Accumulated depreciation and amortization                    566,533               515,042      
                                                                --------------       --------------                          
      
   Total property and equipment                                       263,102               312,866      
                                                                --------------       --------------     
                                                                                                    
                                                                                                    
Other assets:                                                                                       
   Deposits                                                            28,298                28,298      
   Intangible assets, net of accumulated amortization of         
     $544,322 and $382,019                                          2,434,572             2,596,875    
                                                                ----------------     --------------   
      Total other assets                                            2,462,870             2,625,173                              
                                                                ----------------     --------------   
      Total assets                                              $   5,614,371        $    6,507,940       
                                                                ===============      ==============
                                                                                                            
                                                                       
</TABLE>









                          The accompanying notes are an
                       integral part of these statements.

                                       1

<PAGE>
    

                    FRANKLIN OPHTHALMIC INSTRUMENTS CO., INC.

                            CONDENSED BALANCE SHEETS

                                   (Continued)


                      LIABILITIES AND STOCKHOLDERS' EQUITY

<TABLE>
<CAPTION>
                                                                    March 31,        September 30,
                                                                      1996                1995
                                                                   (Unaudited)
                                                                ------------------  -----------------
Current liabilities:
<S>                                                               <C>                <C>                                          
   Bank overdrafts                                                $   62,649         $  251,078                                   
   Current portion of long-term debt                                 296,880            324,660
   Accounts payable                                                2,034,902          2,070,526
   Notes payable to bank                                           4,396,126          4,396,126
   Current portion of capitalized lease obligations                   16,398             14,687
   Deposits                                                            9,513             24,243
   Accrued liabilities                                               752,577            666,346   
   Notes payable to related parties                                  305,000            207,679
                                                                    --------           -------

      Total current liabilities                                    7,874,048          7,955,345
                                                                  ----------         ---------

Long-term debt:
   Long-term debt, less current portion                              368,235            378,128
   Capitalized lease obligations, less current portion                39,067             53,186
                                                                  -----------        ----------
      Total long-term debt                                           407,302            431,314
                                                                  -----------        ----------
      
      Total liabilities                                            8,281,350          8,386,659
                                                                  -----------        ----------

Stockholders' equity (deficit):
   Common stock: $0.001 par value; authorized
    25,000,000 shares; 7,672,525 and 7,656,025 shares
    issued and outstanding at March 31, 1996 and
    September 30, 1995                                                 7,673              7,656
   Additional paid-in capital                                      8,252,378          8,240,020
   Accumulated deficit                                           (10,927,030)       (10,126,395)
                                                                -------------       ------------

      Total stockholders' equity (deficit)                        (2,666,979)        (1,878,719)
                                                                  ----------         ---------- 

 
      Total liabilities and stockholders' equity (deficit)        $5,614,371         $6,507,940
                                                                 ===========        ===========


</TABLE>








                          The accompanying notes are an
                       integral part of these statements.


                                       2
<PAGE>

                    FRANKLIN OPHTHALMIC INSTRUMENTS CO., INC.

                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

                                   (Unaudited)
<TABLE>
<CAPTION>


                                           For the three months           For the six months
                                                  ended                         ended
                                                 March 31,                     March 31,
                                       -----------------------------  ------------------------------

                                           1995           1996             1995           1996
                                           ----           ----             ----           ----
                                                                      (as restated-
                                                                       See Note 2)

<S>                                      <C>             <C>            <C>             <C>        
Sales                                    $ 3,350,207     $2,197,045     $  8,153,000    $ 4,572,728

Less:
  Cost of Sales                            2,658,402      1,682,263        6,635,074      3,516,939
  Selling, general and
     administrative expenses                 897,969        725,744        2,596,809      1,531,317
  Inventory loss                                   -              -          770,033              -
  Restructuring charge expense              (200,000)             -          230,525              -
                                       -------------- --------------  --------------- --------------
Income (loss) from operations                 (6,164)      (210,962)      (2,079,441)      (475,528)                              
                                       -------------- --------------  --------------- --------------

Other income (expenses):
   Interest income                                61             45            7,471             45
   Interest expense                         (135,631)      (170,053)        (280,813)      (325,152)
   Other income (expense)                     20,067              -           20,250              -
                                       -------------- --------------  --------------- --------------

      Other income (expense), net           (115,503)      (170,008)        (253,092)      (325,107)
                                       -------------- --------------  --------------- --------------


Net income (loss)                        $  (121,667)    $ (380,970)     $(2,332,533)   $  (800,635)
                                       ============== ==============  =============== ==============

Loss per common share:

   Net Loss                              $     (0.03)    $    (0.05)    $      (0.57)   $     (0.10)                              
                                       ============== ==============  =============== ==============

   Weighted average number of
      common shares outstanding                           
                                           4,129,051      7,672,525        4,119,410      7,670,463
                                       ============== ==============  =============== ==============



</TABLE>









                          The accompanying notes are an
                       integral part of these statements.

                                       3

<PAGE>
                    FRANKLIN OPHTHALMIC INSTRUMENTS CO., INC.

                 CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

                                   (Unaudited)
<TABLE>
<CAPTION>


                                                                        For the six months ended
                                                                                March 31,
                                                                      --------------------------------
                                                                           1995               1996
                                                                           ----               ----
                                                                       (as restated-
                                                                        See Note 2)
Cash flows from operating activities:
<S>                                                                     <C>              <C>         
   Net income (loss)                                                    $ (2,332,533)    $ (800,635)
   Adjustments to reconcile net income (loss)
    to net cash used in operating activities:
      Depreciation                                                            60,104         51,491
      Amortization                                                            87,924        162,303
      Other                                                                     (183)
      Changes in current assets and liabilities:
         Accounts receivable                                                 869,300        318,483
         Inventory                                                         1,188,808        437,606
         Prepaid expenses                                                    (38,794)       (74,588)
         Other assets                                                          5,507              -
         Accounts payable, trade and accrued liabilities                     193,678         35,879
                                                                      ---------------- ---------------
      Net cash used in operating activities                                   33,811        130,539
                                                                      ---------------- ---------------

Cash flows from investing activities:
   Proceeds from sale of equipment (as received )                             17,750              -
   Acquisition of equipment                                                  (38,421)        (1,727)
                                                                      ---------------- ---------------
      Net cash used in investing activities                                  (20,671)        (1,727)
                                                                      ---------------- ---------------
Cash flows from financing activities:
   Increase (decrease) in bank overdrafts                                   (520,107)      (188,427)
   Net proceeds from issuance of common stock                                 34,200         12,375
   Increase (decrease) in long-term debt                                      19,154       (37,673)
   Decrease in long-term debt                                                (25,835)
   Increase (decrease) in capital leases                                       9,574       (12,408)
   Repayment of debt - related party                                          (8,009)
   Proceeds from issuance of promissory notes-related party                  200,000         97,321
                                                                      ---------------- ---------------
Net cash provided by financing activities                                   (291,023)      (128,812)
                                                                      ---------------- ---------------
Net decrease in cash                                                       (277,883)              -
                                                                                                  
Cash and cash equivalents at beginning of period                            277,883               -
                                                                      ---------------- ---------------
Cash and cash equivalents at end of perio                               $         -      $        -
                                                                      ---------------- ---------------


</TABLE>








                          The accompanying notes are an
                       integral part of these statements.

                                       4

<PAGE>





                    FRANKLIN OPHTHALMIC INSTRUMENTS CO., INC.
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (Unaudited)

1.       SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

         (A)      Basis of Presentation
                  ---------------------
         The condensed consolidated financial statements include the accounts of
Franklin  Ophthalmic  Instruments  Co., Inc. (the  "Company") and its previously
wholly-owned subsidiary Midwest Ophthalmic  Instruments,  Inc. ("MOI") which was
merged into the Company  during the second quarter of fiscal 1995. The condensed
consolidated  financial  statements  have been prepared by the Company,  without
audit,  pursuant to the rules and  regulations  of the  Securities  and Exchange
Commission.  In the opinion of management,  the condensed consolidated financial
statements include,  except as discussed in Note 2, all adjustments necessary to
present fairly the financial position,  results of operations and cash flows for
the periods presented. Such adjustments consist of normal recurring accruals and
the  adjustments   described  in  Note  2.  Certain   information  and  footnote
disclosures  normally  included in financial  statements  prepared in accordance
with generally  accepted  accounting  principles  have been condensed or omitted
pursuant to such rules and  regulations,  although the Company believes that the
disclosures are adequate to make the information  presented not misleading.  The
condensed  consolidated  financial  statements and these notes should be read in
conjunction with the consolidated  financial  statements of the Company included
in the Company's  Annual Report on Form 10-KSB for the year ended  September 30,
1995.

         The  results of  operations  for interim  periods  are not  necessarily
indicative of the results to be expected for a full year.


         (B)      Significant Matters Affecting Comparability
                  -------------------------------------------
         During  the year  ended  September  30,  1995,  the  Company  underwent
significant  structural,  management and  operational  changes,  and as a result
thereof the operating  results for the three and six months ended March 31, 1995
lack, in several  respects,  comparability  to the results of operations for the
three and six months ended March 31, 1996.

         Until  the  second  quarter  of  fiscal  1995,  the  Company   operated
facilities in Hayward, California and Lawrenceville,  Georgia (which represented
the Company's original operations), Jacksonville, Florida (which was acquired in
January 1994 in the  Company's  acquisitions  of certain  assets of  Progressive
Ophthalmic Instruments,  Inc. ("POI") and Romeoville,  Illinois (which was added
with the Company's July 1994  acquisition  of MOI.  During the second quarter of
fiscal 1995, the Company underwent a change in management,  as further described
below,  and new  management  decided to close all but the  Romeoville,  Illinois
facility.

         Pursuant to an  agreement,  dated April 1, 1995,  between the  Company,
Robert A. Davis (the Company's former Chief Executive  Officer,  Chief Financial
Officer,  and  President),  certain  partnerships  in  which  Mr.  Davis  has an
interest,  Michael  J.  Carroll,  James  J.  Urban  and  Brian M.  Carroll  (the
"Separation  Agreement:),  Mr.  Davis  and Mr.  Dallas  Talley,  resigned  their
positions  with the  Company and  Messrs.  Michael  Carroll and James Urban were
elected  to  fill  the  vacancies  on the  Company's  board  of  directors.  The
Separation  Agreement also provided that: (I) Mr. Davis would contribute 800,000
shares of the Common Stock back to the Company; and (ii) Mr. Davis would forgive
$200,000 owed to him by the Company. Under the Separation Agreement, the Company
agreed to  indemnify  Mr. Davis for and against any claims for fraud and certain
types of negligence,  which might be made in connection with Mr. Davis's service
as an officer or director of the Company.

                                       5

<PAGE>



                    FRANKLIN OPHTHALMIC INSTRUMENTS CO., INC.
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (Unaudited)
                                   (Continued)

         (B)      Significant Matters Affecting Comparability (Continued)
                  ------------------------------------------------------
         Subsequently,  the new management of the Company  decided to attempt to
restructure the Company's  operations around the MOI operations acquired in July
1994. As a result, the California, Florida and Georgia facilities were closed.

         A result of these substantial changes in the Company's  operations,  is
that  operating  results  for the six months  ended March 31, 1995 and 1996 lack
comparability.  The  results  for the three and six months  ended March 31, 1995
reflect MOI and the Company operating  separately and prior to the restructuring
efforts  initiated  by current  management  during the second  quarter of fiscal
1995. Conversely, the operating results for the three and six months ended March
31, 1996 are predominated by the results of MOI's  operations,  which formed the
core of the Company's activities after the changes discussed above.

         (C)      Intangible Assets
                  -----------------
         Intangible  assets  include  employment  contracts and goodwill,  which
represents  the excess of cost over fair market value of net assets  acquired in
the purchase of MOI and in the acquisition of individual distributorships.

         It is the Company's policy to periodically  evaluate the carrying value
of its operating assets,  including goodwill,  and to recognize impairments when
the estimated  discounted  future net operating  cash flows to be generated from
the use of the assets is less than their carrying  value.  The Company  measures
impairment  of goodwill by the  difference  between the  carrying  value and the
estimated discounted cash flows from the assets.

         Effective July 1, 1995, the Company  reduced the estimated  useful life
for goodwill  related to the acquisition of MOI (see Note 4) from 30 years to 15
years.  This change was made,  retroactively to the beginning of fiscal 1995, to
reflect  management's  revised  estimate of the useful life of the MOI goodwill,
which was revised to reflect the  significance  of certain key  personnel at MOI
and the rate at which the ophthalmic industry could change.

         Amortization  expense  charged to  operations  was  $87,924 for the six
months  ended March 31,  1995 and  $162,303  for the six months  ended March 31,
1996.


2.       CORRECTION OF ERRORS

         In  January  1995,  a  special  committee  of the  Company's  board  of
directors  initiated an  investigation  into the  circumstances  surrounding the
timing  and  causes  of  certain  inventory  allowances,   sales  and  bad  debt
provisions,  and goodwill  provisions  recorded in the fourth  quarter of fiscal
1994 and the first  quarter of fiscal 1995.  As a result of that  investigation,
the Company  determined  that in both fiscal 1993 and fiscal 1994,  the Company:
(i) recorded sales for products not actually ordered by or shipped to customers;
(ii) recorded  sales in advance of the actual  shipment of the  products;  (iii)
failed to provide adequate  allowances for slow moving or obsolete  inventories;
and (iv) failed to provide adequate allowances for doubtful accounts receivable.
As a result of the above, the Company's  consolidated  financial  statements for
fiscal 1993 and 1994,  the quarter ended  December 31, 1994,  and the six months
ended March 31, 1995 were restated to correct the aforementioned errors.

                                       6

<PAGE>

                    FRANKLIN OPHTHALMIC INSTRUMENTS CO., INC.
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (Unaudited)
                                   (Continued)

2.       CORRECTION OF ERRORS (Continued)

         The investigation commenced in January 1995 also attempted to determine
the  specific  causes,  and the timing  thereof,  of the $2.5  million  and $1.1
million  inventory  loss  provisions  recorded and  reflected  in the  financial
statements  for  fiscal  1994 and the  first  quarter  of  fiscal  1995.  It was
determined in large part, the 1994 inventory write-downs and the majority of the
1995  inventory  write-downs  were  most  likely  the  result  of  the  loss  of
inventories   caused  by  poor  controls  over   inventories   issued  to  sales
representatives and the transfer of the Company's inventories previously located
in California to Florida in  connection  with the transfer of its  operations to
that location after the  acquisition  of POI. Of the $1.1 million  write-down in
fiscal 1995,  $323,967 was determined to represent the costs of sales associated
with the sales  previously  recorded in fiscal 1994,  and now recorded in fiscal
1995,  and  accordingly  that amount is now included in cost of sales.  However,
because of the poor  controls  and  recordkeeping,  the  Company was not able to
determine  the causes and timing with  specificity,  other than to conclude that
the $2.5 million and the  remaining  $770,033  losses were  properly  treated as
fiscal 1994 and fiscal 1995 charges, respectively.

         The  adjustments  described  above and recorded in the first quarter of
fiscal 1995 changed the amounts  previously  reported by the Company for the six
months ended March 31, 1995 as follows:

         (i) Charges  against  sales of $228,681,  previously  recorded  against
sales in the first  quarter  of fiscal  1995 as the  result of sales  improperly
recorded in fiscal 1994,  were  eliminated  as the result of the  correction  of
fiscal 1994 to remove those sales from that period.

         (ii) Sales of  $185,194,  which had  previously  been  recorded  in the
fourth quarter of fiscal 1994, were eliminated from that period, and recorded in
the first quarter of fiscal 1995,  because it was  determined  that the products
were not shipped until after September 30, 1994.

         (iii) An  additional  allowance  for  doubtful  accounts of $26,000 was
recorded in the quarter ended December 31, 1994,  representing the net effect of
(a) allowances  originally recorded in that period, but eliminated as the result
of the restatement of fiscal 1994; and (b) additional allowances recorded in the
first quarter of fiscal 1995 because it was  determined  that the net realizable
value of accounts receivable had not been properly assessed.


         The adjustments described above changed the amounts previously reported
by the  Company  for net loss and net loss per  share for the six  months  ended
March 31, 1995 as follows:

Net loss
         As previously reported                        $2,719,408
         As restated                                   $2,332,533

Net loss per share
         As previously reported                        $     (.66)
         As restated                                   $     (.57)

                                       7

<PAGE>



                    FRANKLIN OPHTHALMIC INSTRUMENTS CO., INC.
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (Unaudited)
                                   (Continued)

3.       GOING CONCERN

         The accompanying  consolidated  financial statements have been prepared
on the  assumption  that  the  Company  will  continue  as a going  concern  and
therefore assume the realization of the Company's assets and the satisfaction of
its liabilities in the normal course of operations.

         The  Company  is in  default  under the terms of its  revolving  credit
facility with Silicon Valley Bank ("Silicon"),  which is the Company's principal
credit facility. Additionally, in part because of that default and the resulting
inability to obtain additional  working capital,  the Company has been unable to
make timely  reductions  in the amount owed to its product  suppliers  and, as a
consequence,  is currently  unable to obtain  normal trade credit terms and must
purchase products with limited credit terms or with payment on delivery.

         The  Company's  ability to  continue as a going  concern is  ultimately
dependent  on its  ability  to  increase  sales to a level that will allow it to
operate  profitably and generate  positive  operating  cash flows.  Although the
reduction  of  expenses,  which was begun in the last half of fiscal 1995 and is
continuing  in  fiscal  1996,  can   contribute  to  the  necessary   return  to
profitability,  achieving  profitability  without  an  increase  in sales  would
require much greater  levels of expense  reduction and in all  likelihood  could
only be accomplished  through  significant  reduction and  restructuring  of the
nature and scope of the Company's operations.

         The Company's sales have been adversely affected by its lack of working
capital and  liquidity,  which has limited its marketing  efforts and in certain
instances has  prevented it from  obtaining  products to fill  customer  orders.
Accordingly,  to  increase  sales the  Company  must first  resolve  its working
capital shortage.

         The Company  received from Silicon a letter  proposing the terms of the
elimination of the  approximately  $4.7 million currently owed by the Company to
Silicon under the revolving credit facility.  Under the proposal,  approximately
$2.1  million  would be repaid from the  proceeds of a new credit  facility  the
Company  would  obtain from  another  lending  institution  and the  proceeds of
private  placements of equity  securities the Company would  undertake,  and the
remaining  balance of $2.6  million  would be  extinguished  by the  issuance to
Silicon of  approximately  1.7 million  shares of the  Company's  Common  Stock.
Silicon's  proposal was  conditioned  on, among other things:  (i) the Company's
simultaneous  receipt of at least  $1.4  million of  proceeds  from the  private
placement of common stock; and (ii) the Company's  conversion of certain amounts
owed to trade suppliers into long-term  notes.  Although the letter from Silicon
expired on April 15, 1996, the Company is currently  negotiating with Silicon to
extend its proposal on terms substantially similar to those set forth above.

         To  complete  such a  restructuring  the  Company  would be required to
obtain a new accounts  receivable and inventory based credit facility from which
to fund a  substantial  portion  of the cash  payment  under the  proposal  from
Silicon  and  finance  ongoing  operations.  The  Company  has been  engaged  in
discussions  with several  lenders and,  although to date no formal proposal has
been made or agreed  to,  management  believes  that such new  financing  can be
obtained.  The Company  also does not have any firm  commitments  for the equity
investments that the  implementation of the Silicon proposal would require,  but
it has received verbal indication of the availability of such funds.

         Management  believes that the completion of a restructuring of its bank
financing  within  the  parameters  described  above  would  allow it to  reduce
outstanding  trade debt and obtain trade credit.  Those steps,  taken  together,
would,  in the  opinion  of  management,  allow the  Company  to  achieve  sales
increases by reducing the limiting  effects that the  Company's  lack of working
capital have had on marketing  and the ability to obtain the products  necessary
to accept and fill  customer  orders on a timely  basis.  The increases in sales
would  ultimately  allow the  Company to return to  profitability  and  generate
positive cash flows.

                                       8

<PAGE>

                    FRANKLIN OPHTHALMIC INSTRUMENTS CO., INC.
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (Unaudited)
                                   (Continued)

         There  can  be  no  assurance  that  a  definitive  agreement  for  the
elimination of the amounts  outstanding under the Silicon credit facility can be
reached  or if one is  reached,  that the  Company  would be able to obtain  the
necessary  new debt and equity  financing  to  implement  the Silicon  proposal.
Additionally, although it has been represented to the Company by trade creditors
that its credit lines would be increased upon the restructuring described above,
there can be no assurance  that the  completion  of such a  restructuring  would
allow the Company to obtain meaningful trade credit, or that all of these steps,
if completed,  will in fact allow the Company to increase its sales. The failure
of any of these  steps  would  force the  Company  to  significantly  reduce its
operations  in order to reduce  expenses  or take other  significant  actions to
resolve its liquidity constraints.


4.       SHORT TERM DEBT - RELATED PARTY

         In September 1995, Michael J. Carroll and James J. Urban, the Company's
President/Chief  Executive  Officer  and Senior Vice  President/Chief  Operating
Officer,  respectively,  loaned an  aggregate  of  $100,000  to the  Company  in
exchange for 90-day  promissory notes. In addition,  Linda Zimdars,  a member of
the Company's board of directors, loaned $100,000 to the Company in exchange for
90-day promissory  notes. The notes to Ms. Zimdars are personally  guaranteed by
Messrs.  M.  Carroll and Urban.  The notes bear  interest  at 15% per annum.  In
December 1995, a payment of $10,000 was made on the note to Messrs.  Carroll and
Urban and a payment of  $10,000  was made on the note to Ms.  Zimdars.  In April
1996, the notes were amended to extend their maturity to July 1, 1996.

         In December  1995,  the Company  borrowed an  additional  $280,000 from
related parties under 60-day  promissory  notes bearing interest at 6% per annum
and note  origination  fees of $17,000 (6%).  Of the aggregate of $280,000:  (i)
$50,000 was borrowed from each of Michael Carroll and James Urban;  (ii) $80,000
was borrowed from Ms.  Zimdars;  and (iii)  $100,000 was borrowed from Tiger Eye
Capital, L.L.C. ("Tiger Eye"). The notes were repaid in February 1996. Tiger Eye
has consulting  agreements with the Company which provide for the issuance of an
aggregate of 800,000 shares of common stock in connection  with the rendering of
investor and public relations services.

         In February  1996,  the Company  borrowed an  additional  $150,000 from
related parties under 24-day  promissory  notes bearing  interest at the rate of
Prime plus 1% per annum above the prime rate. A loan  origination  fee of 3% was
also paid. Of the  aggregate of $150,000,  (i) $50,000 was borrowed from each of
Michael  Carroll  and James  Urban;  (ii) and $50,000  was  borrowed  from Linda
Zimdars. In March 1996, a payment of $12,500 was made to each of Messrs. Carroll
and Urban,  and in May 1996,  the  balance of the notes to Messrs.  Carroll  and
Urban were repaid. The note to Ms. Zimdars was repaid in May, 1996.


5.       COMMITMENTS

         On May 10,  1996 the Company  consolidated  its  facilities  located in
buildings in  Romeoville,  Illinois.  In  connection  with the  relocation,  the
Company was released from its obligations  under the existing  facilities  lease
and entered into a new lease  commencing on May 10, 1996 for a term of 60 months
with a monthly obligation of approximately $10,100.

                                       9



<PAGE>

Item 2.   Management's  Discussion  and  Analysis  of  Financial  Condition  and
          Results of Operations

General

         During  fiscal  1995,  the Company  underwent  significant  structural,
management  and  operational  changes,  and as a result  thereof  the  operating
results for the six months  ended March 31,  1996 lack,  in several  significant
respects,  comparability  to the results of operations  for the six months ended
March 31, 1995

         Until  the  second  quarter  of  fiscal  1995,  the  Company   operated
facilities in Hayward,  California ("the Hayward  Facility") and  Lawrenceville,
Georgia ("the Georgia  Facility"),  a Jacksonville,  Florida facility (which was
added with the Company's  acquisition  of  Progressive  Ophthalmic  Instruments,
Inc.) and a Romeoville,  Illinois  facility  (which was added with the Company's
acquisition  of MOI).  During the second  quarter of fiscal  1995,  the  Company
underwent a change in management, as described below, and, under new management,
decided to close all but the Romeoville operations.

         Pursuant to an  agreement,  dated April 1, 1995,  between the  Company,
Robert A. Davis (the Company's former chief executive  officer,  chief financial
officer, and president), certain partnerships in which Mr. Davis has an interest
, and Michael J. Carroll,  James J. Urban and Brian M. Carroll (the  "Separation
Agreement"),  Mr. Davis and Mr. Dallas Talley  resigned their positions with the
Company  and  Messrs.  Michael  Carroll  and James  Urban  were  elected to fill
vacancies on the Company's  board of directors (the "Board of  Directors").  The
Separation  Agreement also provided that: (I) Mr. Davis would contribute 800,000
shares of Common  Stock back to the Company;  and (ii) Mr.  Davis would  forgive
$200,000 owed to him by the Company. Under the Separation Agreement, the Company
agreed to indemnify  Mr.  Davis for any claims,  other than claims for fraud and
certain types of negligence,  which might be made in connection  with Mr. Davis'
service as an officer or director of the Company.

         In January  1995,  the new  management  of the  Company  commenced  its
attempt to  restructure  the  Company's  operations  around  the MOI  operations
acquired by the Company in July 1994. As a result, the California Facility,  the
Jacksonville  facility and the Georgia Facility were closed.  Additionally,  the
Company instituted throughout its sales force compensation  structures and other
policies similar to those historically used by MOI, which included:  (i) the use
of sales quotas and scheduling  requirements;  (ii) a commission  structure that
contains   lower   base  and  higher   incentive   components;   (iii)   greater
accountability  for  expenses  and  inventory;  and (iv)  limits on  competitive
activities.  As a result of these  changes,  approximately  50% of the Company's
prior sales  representatives  terminated their  representation of the Company or
were  dismissed.  Some but not all of these  representatives  have been replaced
and,  as a result,  the Company has lost  representation  in certain  geographic
areas or with certain accounts previously serviced by it.

         It is as a  result  of  these  substantial  changes  in  the  Company's
operations,  that operating results for the three and six months ended March 31,
1995 and March 31, 1996 lack comparability. The three and six months ended March
31, 1995 results reflect MOI and the Company  operating  separately and prior to
the  restructuring  efforts  initiated by current  management  during the second
quarter of fiscal 1995. Conversely,  the operating results for the three and six
months ended March 31, 1996 are predominated by the results of MOI's operations,
which formed the core of the Company's  activities  after the changes  discussed
above.

Restatement for the six months ended March 31, 1995

         In  January  1995,  a  special  committee  of the  Board  of  Directors
initiated an  investigation  into the  circumstances  surrounding the timing and
cause  of  certain  inventory  allowances,  sales  and bad debt  provision,  and
goodwill  provision  recorded  in the fourth  quarter of fiscal  1994 and in the
first quarter of fiscal 1995. As a result of the investigation,  the Company has
determined  that, in both fiscal 1993 and 1994, the Company:  (i) recorded sales
for products  not actually  ordered by or shipped to  customers;  (ii)  recorded
sales in advance of the actual shipment of the products; (iii) failed to provide
adequate allowances for slow moving or obsolete inventories;  and (iv) failed to
provide  adequate  allowances for doubtful  accounts  receivable.  The financial

                                       10

<PAGE>

statements  for the years ended  September 30, 1993 and 1994,  the quarter ended
December 31, 1994, and the six months ended March 31, 1995 have been restated to
correct  these  errors  in the  application  of  generally  accepted  accounting
principles. See Note 2 of Notes to Condensed Consolidated Financial Statements.

         The special  investigation  which was  commenced  in January  1995 also
attempted to determine the specific causes, and the timing thereof,  of the $2.5
million and $1.1 million inventory loss provisions recorded and reflected in the
financial  statements  for fiscal  1994 and the first  quarter  of 1995.  It was
determined that, in large part, the 1994 inventory  write-downs and the majority
of the 1995  inventory  write-downs  were most  likely the result of the loss of
inventories   caused  by  poor  controls  over   inventories   issued  to  sales
representatives  and the transfer of the Company's Hayward Facility  inventories
to its Jacksonville, Florida and Lawrenceville, Georgia Facilities in connection
with the transfer of its operations to those  locations after the acquisition of
POI.  Of the $1.1  million  write-down  in the first  quarter  of  fiscal  1995,
$330,000 was  determined to represent the costs of sales  associated  with sales
previously  recorded in fiscal 1994, which had been incorrectly  reversed in the
first  quarter of fiscal 1995,  and  accordingly  that amount is now included in
cost of sales.  However,  because of the poor  controls and  recordkeeping,  the
Company was not able to determine the causes and timing with specificity,  other
than to  conclude  that the $2.5  million  and  remaining  $770,000  losses were
properly treated as fiscal 1994 and fiscal 1995 charges, respectively.

Going Concern and Management's 1996 Plans

         As discussed in the notes to the  financial  statements  and  elsewhere
herein,  the  Company  is in  default  under the terms of its  revolving  credit
facility  with  Silicon,  which  is the  Company's  principal  credit  facility.
Additionally,  in part  because of that default and the  resulting  inability to
obtain  additional  working capital,  the Company has been unable to make timely
reductions in the amount owed to its product  suppliers  and one trade  creditor
has filed a lawsuit  seeking  payment of  outstanding  amounts  owed to it. As a
consequence, the Company is currently unable to obtain normal trade credit terms
and must purchase product with limited credit terms or with payment on delivery.

         The  Company's  ability to  continue as a going  concern is  ultimately
dependent  on its ability to increase its sales to a level that will allow it to
operate  profitably and generate  positive  operating  cash flows.  Although the
reduction  of  expenses  (which was begun in the last half of fiscal 1995 and is
continuing  in  fiscal  1996)  can   contribute  to  the  necessary   return  to
profitability,  achieving  profitability  without  an  increase  in sales  would
require much greater levels of expense  reductions  and in all likelihood  could
only be accomplished  through a significant  reduction and  restructuring of the
nature and scope of the Company's operations.

         The Company's sales have been adversely affected by its lack of working
capital and liquidity,  which has limited its marketing  efforts and, in certain
instances,  has prevented it from  obtaining  products to fill customer  orders.
Accordingly,  to  increase  sales the  Company  must first  resolve  its working
capital shortage.

         The Company  received a letter from Silicon  proposing the terms of the
elimination of  approximately  $4.7 million  currently owed to Silicon under the
revolving credit facility. Under the proposal,  approximately $2.1 million would
be repaid from the proceeds of a new lending facility and private  placements of
its equity  securities  which the Company  would  undertake,  and the  remaining
balance of $2.6  million  would be  extinguished  by the  issuance to Silicon of
approximately  1.7  million  shares of the  Company's  common  stock.  Silicon's
proposal was conditioned on, among other things: (i) the Company's  simultaneous
receipt of at least $1.4  million of  proceeds  from the  private  placement  of
common stock; and (ii) the Company's conversion of certain amounts owed to trade
suppliers into  long-term  debt.  Although the proposal from Silicon  expired on
April 15, 1996, the Company is currently  negotiating with Silicon to extend its
proposal on terms substantially similar to those set forth above.

         To  complete  such a  restructuring  the  Company  would be required to
obtain a new accounts  receivable and inventory based credit facility from which
to fund a  substantial  portion  of the cash  payment  under the  proposal  from
Silicon and to finance  ongoing  operations.  The  Company  has been  engaged in
discussions  with several  lenders,  and although to date no formal proposal has
been made or agreed  to,  management  believes  that 

                                       11

<PAGE>


such new  financing  can be  obtained.  The Company  also does not have any firm
commitments for the equity  investments that the  implementation  of the Silicon
proposal  would  require,   but  it  has  received  verbal   indication  of  the
availability of such funds.

         Management  believes that the completion of a restructuring of its bank
financing  within  the  parameters  described  above  would  allow it to  reduce
outstanding  trade debt,  to obtain  trade  credit and  resolve  the  litigation
discussed  above.  Those  steps,  taken  together,  would,  in  the  opinion  of
management,  allow the Company to achieve sales by reducing the limiting effects
that the Company's lack of working  capital has had on marketing and the ability
to obtain the products  necessary to accept and fill customer orders on a timely
basis.  The increases in sales would  ultimately  allow the Company to return to
profitability and generate positive cash flows.

         There  can  be  no  assurance  that  a  definitive  agreement  for  the
elimination of the amounts  outstanding under the Silicon credit facility can be
reached  or if one is  reached,  that the  Company  would be able to obtain  the
necessary new debt and/or equity  financings to implement the Silicon  proposal.
Additionally, although it has been represented to the Company by trade creditors
that its credit lines would be increased upon the restructuring described above,
there can be no assurance  that the  completion  of such a  restructuring  would
allow the Company to obtain meaningful trade credit, or that all of these steps,
if completed, will in fact allow the Company to increase its sales.. The failure
of any of these  steps  would  force the  Company  to  significantly  reduce its
operations in order to reduce  expenses or take other  significant  actions,  to
resolve it liquidity constraints.


Results of Operations

         Sales  declined by $3,580,272  to  $4,572,728  for the six months ended
March 31, 1996 from  $8,153,000  for the six months  ended March 31,  1995.  The
previously  discussed  changes  in  the  Company's  sales  operations,  and  the
Company's  lack of working  capital,  were the  dominant  reason for the overall
decline in sales.

         The Company's  gross margin on sales  decreased from $1,517,926 for the
six months ended March 31, 1995 to $1,055,789 for the six months ended March 31,
1996. Gross margin, as a percentage of sales, was 18.6% for the six months ended
March 31, 1995 and 23.1% for the six months ended March 31,  1996.  The increase
in margin as a percentage  of sales for the six months ended March 31, 1996 from
the  percentage  for the six months ended March 31, 1995 and from the  Company's
historical  percentage is primarily  attributable  to the  predominance of MOI's
operations  in the  operating  results for the six months  ended March 31, 1996.
MOI's sales  include a greater  level of products it has  designed,  and related
technical services,  and as a result have historically  generated a higher gross
margin that those of the Company's other  operations prior to the integration of
MOI. The Company  believes  that MOI's  historical  gross  margin  levels can be
maintained  while efforts are made to increase sales;  however,  there can be no
assurance that attempts to increase sales may not require incentive pricing that
would adversely affect the gross margin percentage.

         Selling,  general and  administrative  ("SG&A") expenses decreased from
$2,596,809  for the six months  ended March 31, 1995 to  $1,531,317  for the six
months ended March 31, 1996. As a percentage of sales,  SG&A expenses were 31.8%
for the six months  ended March 31,  1995,  compared to 33.5% for the six months
ended March 31, 1996. The decrease in SG&A expenses is primarily a result of the
consolidation  and  restructuring  of the  Company's  operations,  as previously
described,  and the lower level of sales.  SG&A  expenses  for six months  ended
March 31, 1996 included approximately $140,000 in professional fees attributable
to the audit of the  Company's  1994 and 1995  fiscal  years  and the  Company's
restructuring efforts.

         In  connection  with  the  closure  of  the  Company's   facilities  in
Jacksonville,  Florida  and  Lawrenceville,  Georgia,  the  Company  recorded  a
restructuring  charge of $430,525  during the first quarter of fiscal 1995.  The
restructuring  charge was  subsequently  reduced in the second quarter of fiscal
1995 upon the execution of a sub-lease  agreement for the Jacksonville,  Florida
facility.

         Interest expense increased from $280,013 for the six months ended March
31, 1995 to $325,152 for the six months  ended March 31,  1996.  The increase in
interest  expense  is  primarily  attributable  to (i)  higher  

                                       12

<PAGE>



interest  rates  occasioned by the increases in prime  interest  rates that took
place during the Company's 1995 fiscal year, (ii) the increase, from 1% over the
prime rate to 3% over the prime rate,  in the interest rate charged on inventory
borrowings  under the Company's line of credit,  (iii) interest charged by trade
creditors on  outstanding  past due  balances,  and (iv)  interest  charged from
private  placements  of short  term debt to related  parties.  See Note 4 of the
Condensed Consolidated Financial Statements.

         As a result of the above,  the Company  reported a loss of $800,635 for
the  six  months  ended  March  31  1996,  compared  to a loss as  restated,  of
$2,331,533 for the six months ended March 31, 1996.

Liquidity and Capital Resources

         Cash flow from  operations  was $130,539 for the six months ended March
31, 1996 and $33,811 for the six months  ended March 31,  1995.  The increase in
operating cash flow for the six months ended March 31, 1996 was primarily due to
reductions in accounts receivable and inventory.

         The Company's  revolving  credit  facility with Silicon,  which allowed
borrowing  based on 80% of  eligible  accounts  receivable  and 50% of  eligible
inventories (net of trade accounts  payable),  became overdrawn as the result of
the fourth quarter 1994 and first quarter 1995 inventory  losses,  which reduced
the available  borrowing  base. On April 1, 1995 Silicon  agreed to extend until
April 15, 1996 the terms of the  original  revolving  credit  agreement,  and to
forbear exercise of its rights thereunder  resulting from the Company's defaults
with respect to the financial covenants,  provided that the Company made certain
scheduled  reductions in both the total amounts  outstanding  under the facility
and in the amount by which the  borrowings  under the facility were in excess of
the amount  available  under the borrowing base formula.  Silicon also agreed to
make an additional advance of $550,000 (the "flat rate loan"). The interest rate
on all  borrowing  was  reset at 3%  above  Silicon's  prime  rate,  subject  to
reduction as the amount of the Company's over formula borrowing  decreased.  The
Company is currently  negotiating  with Silicon to extend its forbearance and to
provide for the  repayment  and  conversion  into equity of amounts  outstanding
under the line of credit.  See Note 3 of the  Condensed  Consolidated  Financial
Statements.

         At various  times  throughout  the remainder of fiscal 1995 and the six
months ended March 31, 1996 the Company was not in compliance with the limits on
total  borrowing  or over  formula  borrowing  contained  in the  April 1,  1995
forbearance  agreement.  As of May 31, 1996, the Company's total indebtedness to
Silicon of approximately  $4,700,000  million  continues to exceed the limits on
total borrowings and over formula borrowings. Such delinquencies constituted new
events of default. As previously discussed,  the Company is currently engaged in
negotiation for the elimination of the Silicon  facility and to date Silicon has
chosen not to exercise  its right  under  these new events of default.  However,
there can be no assurance  that a final  agreement with Silicon will be reached,
and if  reached,  that the  Company  will be able to  implement  the  agreement.
Additionally, there can be no assurance that Silicon will continue to forbear in
the exercise of its rights resulting from the Company's defaults.

         The defaults  under the Silicon credit  facility  prevented the Company
from  obtaining  new  credit  from which to  generate  working  capital  for any
significant  reductions  of amounts owed to trade  creditors.  As a result,  the
Company  continues to be  delinquent  with respect to its  obligations  to trade
creditors,  including the  obligations  the Company had previously  restructured
under  payment  schedules  ranging from eight to twelve  months.  The  Company's
failure to adhere to these  payment  schedules  resulted in one of the creditors
filing a lawsuit  seeking  repayment  of the amounts owed to it and impaired its
ability to obtain new trade credit,  which, as previously  discussed,  adversely
affected  operations  by  preventing  the Company  from  obtaining  the products
necessary to fulfill certain customer orders.

                                       13

<PAGE>


PART II: OTHER INFORMATION

Item 1.  Legal Proceedings.

         On  April  26,  1996,  the  Eastman  Kodak  Company  ("Kodak")  filed a
complaint  against  the  Company in the  United  States  District  Court for the
Northern District of Illinois,  Eastern Division (Docket No. 96C 2519), alleging
default  by the  Company  under  provisions  of a certain  promissory  note (the
"Note") and seeking to recover  amounts  outstanding  under the Note.  The Note,
dated March 7, 1996, is in the principal amount of $296,604.44 and was issued by
the Company in favor of Kodak in  connection  with  repayment of amounts owed by
the Company to Kodak for products  acquired by the Company.  Interest  under the
Note  accrues at the rate of 11% per annum  subject to increase  upon default to
15% per annum.  Repayment of principal and interest under the Note is payable in
installments upon the last day of each month through July 31, 1996. A portion of
the  principal  under the Note was repaid and  reduced by the return to Kodak of
unused product. The complaint alleges that there remains outstanding $223,104.44
(exclusive of interest,  fees, costs and late charges). In addition, the Company
may be subject to legal action as a result of the  delinquency  of debts owed to
Silicon, certain other trade creditors and certain consultants.  The Company has
been  negotiating  with Silicon and its other  creditors to resolve  outstanding
issues  with such  entities  as to repay  such debts on terms  favorable  to the
Company and its creditors. Other than set forth herein, the Company is not aware
of any  pending  or  ongoing  litigation  to which the  Company is or would be a
party.

Item 2.  Changes in Securities.

         There have been no changes in the securities of the Company required to
be disclosed pursuant to this item.

Item 3.  Defaults Upon Senior Securities.

         There has been no material  default with respect to any indebtedness of
the Company required to be disclosed pursuant to this item.

Item 4.  Submission of Matters to a Vote of Security Holders.

         There  have been no matters  submitted  to a vote of  security  holders
during the six months ended March 31, 1996

Item 5.  Other Information

         None

Item 6.  Exhibits and Reports on Form 8-K

         (a)      Exhibits

                  The following exhibits are filed herewith:

                  27       Financial Data Schedule

         (b)      Reports on Form 8-K

                  No reports on 8-K were filed by the Company during the quarter
ended March 31, 1996.

                                       14

<PAGE>




                                   SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Company  has duly  caused  this  report to be  signed on its  behalf by the
undersigned thereunto duly authorized.


                                       FRANKLIN OPHTHALMIC INSTRUMENTS CO., INC.


Date:    June 13, 1996                 By:      /S/      Michael J. Carroll
                                                ---------------------------
                                                Michael J. Carroll, President
                                                and Chief Executive Officer

                                       15

<PAGE>

<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL   INFORMATION  EXTRACTED  FROM  THE
COMPANY'S CONDENSED  CONSOLIDATED  FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED
MARCH 31, 1996 AND IS QUALIFIED  IN ITS ENTIRETY BY REFERENCE TO SUCH  FINANCIAL
STATEMENTS.
</LEGEND>
<MULTIPLIER>                                        1
<CURRENCY>                                 US DOLLARS
       
<S>                                     <C>
<PERIOD-TYPE>                                   6-MOS
<FISCAL-YEAR-END>                         SEP-30-1996
<PERIOD-START>                            OCT-01-1995
<PERIOD-END>                              MAR-31-1996
<EXCHANGE-RATE>                                     1
<CASH>                                              0
<SECURITIES>                                        0
<RECEIVABLES>                               1,014,515
<ALLOWANCES>                                  337,333
<INVENTORY>                                 2,108,334
<CURRENT-ASSETS>                            2,888,399
<PP&E>                                        829,635
<DEPRECIATION>                                566,533
<TOTAL-ASSETS>                              5,614,371
<CURRENT-LIABILITIES>                       7,874,048
<BONDS>                                             0
<COMMON>                                        7,673
                               0
                                         0
<OTHER-SE>                                 (2,674,652)
<TOTAL-LIABILITY-AND-EQUITY>                5,614,371
<SALES>                                     4,572,728
<TOTAL-REVENUES>                            2,375,683
<CGS>                                       3,516,939
<TOTAL-COSTS>                                       0
<OTHER-EXPENSES>                                    0
<LOSS-PROVISION>                                    0
<INTEREST-EXPENSE>                            325,152
<INCOME-PRETAX>                              (800,635)
<INCOME-TAX>                                        0
<INCOME-CONTINUING>                          (800,635)
<DISCONTINUED>                                      0
<EXTRAORDINARY>                                     0
<CHANGES>                                           0
<NET-INCOME>                                 (800,635)
<EPS-PRIMARY>                                   (0.10)
<EPS-DILUTED>                                       0
        


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission